Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease
暂无分享,去创建一个
T. Beach | R. Myers | J. Latourelle | K. Longo | Adam T. Labadorf | A. Dumitriu | J. Golji | B. Gao | Alexandra Dumitriu
[1] A. Abramov,et al. Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease , 2018, Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology.
[2] Alexis Battle,et al. Impact of regulatory variation from RNA to protein , 2015, Science.
[3] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[4] S. Gygi,et al. Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. , 2014, Molecular cell.
[5] Alexander E. Ivliev,et al. Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms , 2014, PloS one.
[6] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[7] B. Kuster,et al. Mass-spectrometry-based draft of the human proteome , 2014, Nature.
[8] N. Sonenberg,et al. Translational control of immune responses: from transcripts to translatomes , 2014, Nature Immunology.
[9] Hagai Bergman,et al. Long Non-Coding RNA and Alternative Splicing Modulations in Parkinson's Leukocytes Identified by RNA Sequencing , 2014, PLoS Comput. Biol..
[10] Dan Xie,et al. Variation and Genetic Control of Protein Abundance in Humans , 2013, Nature.
[11] D. D. Di Monte,et al. Oxidative and nitrative alpha‐synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies , 2013, Journal of neurochemistry.
[12] A. Schapira,et al. α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease , 2013, Molecular Neurobiology.
[13] Sarah R. Langley,et al. Proteomics: from single molecules to biological pathways , 2012, Cardiovascular research.
[14] Wei Li,et al. RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..
[15] E. Lauterbach. Psychotropic drug effects on gene transcriptomics relevant to Parkinson's disease , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[16] J. Vance,et al. Gene Expression Profiles in Parkinson Disease Prefrontal Cortex Implicate FOXO1 and Genes under Its Transcriptional Regulation , 2012, PLoS genetics.
[17] A. DeStefano,et al. Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain , 2012, Parkinson's disease.
[18] Eden R Martin,et al. Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 , 2012, Annals of neurology.
[19] Andrew E. Jaffe,et al. Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .
[20] T. Quintela,et al. Neuroprotective and neuroregenerative properties of metallothioneins , 2012, IUBMB life.
[21] A. Başak,et al. The Central Theme of Parkinson’s Disease: α-Synuclein , 2012, Molecular Neurobiology.
[22] L. Moran,et al. Up-regulation of metallothionein gene expression in Parkinsonian astrocytes , 2011, neurogenetics.
[23] S. Gygi,et al. ms3 eliminates ratio distortion in isobaric multiplexed quantitative , 2011 .
[24] Richard H. Myers,et al. Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease , 2010, Experimental Neurology.
[25] S. Guan,et al. Analysis of proteome dynamics in the mouse brain , 2010, Proceedings of the National Academy of Sciences.
[26] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[27] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[28] M. Naumann,et al. Control of NF-kappaB activation by the COP9 signalosome. , 2010, Biochemical Society transactions.
[29] Wes McKinney,et al. Data Structures for Statistical Computing in Python , 2010, SciPy.
[30] E. Marcotte,et al. Global signatures of protein and mRNA expression levelsw , 2009 .
[31] M. Tansey,et al. Neuroinflammation in Parkinson’s Disease , 2009, Journal of Neuroimmune Pharmacology.
[32] A. Brice,et al. Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.
[33] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[34] Steven P Gygi,et al. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry , 2008, Nature Protocols.
[35] M. Stephens,et al. High-Resolution Mapping of Expression-QTLs Yields Insight into Human Gene Regulation , 2008, PLoS genetics.
[36] Manuel B. Graeber,et al. Neuronal pentraxin II is highly upregulated in Parkinson’s disease and a novel component of Lewy bodies , 2007, Acta Neuropathologica.
[37] G. Deuschl,et al. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. , 2007, Current pharmaceutical design.
[38] John D. Hunter,et al. Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.
[39] Brian E. Granger,et al. IPython: A System for Interactive Scientific Computing , 2007, Computing in Science & Engineering.
[40] A. DeStefano,et al. Sepiapterin reductase expression is increased in Parkinson's disease brain tissue , 2007, Brain Research.
[41] U. Brunk,et al. Metallothionein protects against oxidative stress-induced lysosomal destabilization. , 2006, The Biochemical journal.
[42] C. Tanner,et al. Nongenetic causes of Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[43] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[45] J. Aharon-Peretz,et al. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.
[46] Gordon K Smyth,et al. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.
[47] Daniel R. Scoles,et al. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. , 2003, Human molecular genetics.
[48] M. Gerstein,et al. Comparing protein abundance and mRNA expression levels on a genomic scale , 2003, Genome Biology.
[49] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] Robert Tibshirani,et al. Statistical Significance for Genome-Wide Experiments , 2003 .
[51] P. Mcgeer,et al. Inflammation in Parkinson's disease. , 2001, Advances in neurology.
[52] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[53] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[54] M. Polymeropoulos,et al. Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.
[55] J. Yates,et al. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.
[56] R. Feldman,et al. Environmental Toxins and Parkinson's Disease , 2005 .